Application of a composition of FBP and a plasma concentration stabilizer thereof in preparing drugs for preventing and treating metabolic diseases and metabolic dysfunction related diseases. The FBP may also be a primary form thereof, and a pharmaceutically acceptable salt and hydrate of a prodrug or derivative thereof. The plasma concentration stabilizer refers to a drug or substance for treating diabetes capable of slowing down rapid in vivo degradation of FBP in a pharmaceutical preparation. The composition can cause a higher FBP plasma concentration peak value and a more stable plasma concentration, and can reduce an FBP dosage and thus can reduce the toxicity resulting from a large amount of inorganic phosphorus entering systemic circulation after degradation of a large dosage of FBP.